| Good morning Wake-up Watchlisters! While you're sipping coffee you'll see US stock futures made gains as optimism grew around Congress passing a debt accord to prevent a default. The White House and Republican congressional leaders are intensifying their lobbying efforts. Artificial Intelligence stocks had a big morning, with Nvidia Corp. seeing a 3.3% increase in premarket trading (more on that below). The pressure is now on as proponents of the debt agreement have one week to secure congressional approval before a potential default on June 5 (X Day). While the markets have been volatile due to fear of a debt default, we've used the uncertainty to our advantage in The War Room. Last week we took some huge winners, including a massive 214.53% gain in one trading day after positoning ourselves on the URBN 2 Jun 23 $26 calls. Right now we're guaranteeing members receive 252 winning trades in their first 12 months of membership. Click here to start trading along with us. Here's a look at the top-moving stocks this morning. NVIDIA Corporation (Nasdaq: NVDA) Nividia is up 3.39% premarket after the renowned chipmaker unveiled several new AI-centric products, capitalizing on the generative-AI trend. Notable releases include the Nvidia DGX GH200, a high-powered supercomputer, and Nvidia ACE, a platform leveraging generative AI for video game development. Additionally, advertising giant WPP plans to utilize Nvidia's platforms and generative AI to construct a content engine for ad production. These announcements follow Nvidia's impressive surge in share prices, driven by strong second-quarter revenue projections, particularly in the data center business. With semiconductor companies like NVDA surging, it's vital to learn more about a darker element in the latest tech boom. The truth is China has a plan – a sinister one. And if the US doesn't act now – it could drastically reduce the quality of life for Americans. Click here to learn what China is up to and why a US stock could surge 525% as a result. Iovance Therapeutics (Nasdaq: IOVA) Iovance Therapeutics is up 15.23% in premarket trading following the announcement that the U.S. FDA had accepted its biologics license application (BLA) for lifileucel, the company's lead pipeline candidate for melanoma treatment. The BLA seeks accelerated approval for lifileucel in advanced unresectable or metastatic melanoma patients who have progressed after prior anti-PD-1/L1 therapy. The FDA has granted the BLA priority review and no advisory committee meeting is currently planned. If approved, lifileucel will become the first FDA-approved personalized, one-time cell therapy for melanoma patients, addressing the limited treatment options available after standard-of-care medications. Iovance's stock has shown a year-to-date increase of 18.2%, outperforming the industry's 9.2% decline. | 
Post a Comment
Post a Comment